IPO Comments to CNIPA on Draft Amendments to the Measures for the Administration of Patent Priority Examination
IPO Comments to CNIPA on Draft Amendments to the Measures [...]
You Can’t (Always) Claim What You Didn’t Describe: U.S. and European Perspectives on Chemical Patents
You Can’t (Always) Claim What You Didn’t Describe: U.S. and [...]
IPO Amicus Brief in Hikma Pharmaceuticals USA Inc., v. Amarin Pharma, Inc., 24-889
IPO Amicus Brief in Hikma Pharmaceuticals USA Inc., v. Amarin [...]
IPO Comments on Draft Agreement on Cross-Border Aspects of Client-Patent-Attorney Privilege
IPO Comments on Draft Agreement on Cross-Border Aspects of Client-Patent-Attorney [...]